Elucidation of the effect of plumbagin on the metastatic potential of B16F10 murine melanoma cells via MAPK signalling pathway

Melanoma is the most dangerous form of skin cancer with a very poor prognosis. Melanoma develops when unrepaired DNA damage causes to skin cells to multiply and form malignant tumors. The current therapy is limited by the highly ability of this disease to metastasize rapidly. Plumbagin is a naphthoq...

Full description

Saved in:
Bibliographic Details
Published inExperimental dermatology Vol. 29; no. 4; pp. 427 - 435
Main Authors Alem, Fatima‐Zahra, Bejaoui, Meriem, Villareal, Myra O., Rhourri‐Frih, Boutayna, Isoda, Hiroko
Format Journal Article
LanguageEnglish
Published Denmark Wiley Subscription Services, Inc 01.04.2020
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Melanoma is the most dangerous form of skin cancer with a very poor prognosis. Melanoma develops when unrepaired DNA damage causes to skin cells to multiply and form malignant tumors. The current therapy is limited by the highly ability of this disease to metastasize rapidly. Plumbagin is a naphthoquinone (5‐hydroxy‐2‐methyl‐1, 4‐naphthoquinone), isolated from the roots of medicinal plant Plumbago zeylanica, and it is widely present in Lawsonia inermis L. It has been shown that plumbagin has an anti‐proliferative and anti‐invasive activities in various cancer cell lines; however, the anti‐cancer and anti‐metastatic effects of plumbagin are largely unknown against melanoma cells. In this study, we evaluated the effect of plumbagin on B16F10 murine melanoma cells . Plumbagin decreased B16F10 cell viability as well as the cell migration, adhesion, and invasion. The molecular mechanism was studied, and plumbagin downregulated genes relevant in MAPK pathway, matrix metalloproteinases (MMP's), and cell adhesion. Furthermore, plumbagin elevated the expression of apoptosis and tumors suppressor genes, and genes significant in reactive oxygen species (ROS) response. Taken together, our findings suggest that plumbagin has an anti‐invasion and anti‐metastasis effect on melanoma cancer cells by acting on MAPK pathway and its related genes.
AbstractList Melanoma is the most dangerous form of skin cancer with a very poor prognosis. Melanoma develops when unrepaired DNA damage causes to skin cells to multiply and form malignant tumors. The current therapy is limited by the highly ability of this disease to metastasize rapidly. Plumbagin is a naphthoquinone (5‐hydroxy‐2‐methyl‐1, 4‐naphthoquinone), isolated from the roots of medicinal plant Plumbago zeylanica, and it is widely present in Lawsonia inermis L. It has been shown that plumbagin has an anti‐proliferative and anti‐invasive activities in various cancer cell lines; however, the anti‐cancer and anti‐metastatic effects of plumbagin are largely unknown against melanoma cells. In this study, we evaluated the effect of plumbagin on B16F10 murine melanoma cells . Plumbagin decreased B16F10 cell viability as well as the cell migration, adhesion, and invasion. The molecular mechanism was studied, and plumbagin downregulated genes relevant in MAPK pathway, matrix metalloproteinases (MMP's), and cell adhesion. Furthermore, plumbagin elevated the expression of apoptosis and tumors suppressor genes, and genes significant in reactive oxygen species (ROS) response. Taken together, our findings suggest that plumbagin has an anti‐invasion and anti‐metastasis effect on melanoma cancer cells by acting on MAPK pathway and its related genes.
Abstract Melanoma is the most dangerous form of skin cancer with a very poor prognosis. Melanoma develops when unrepaired DNA damage causes to skin cells to multiply and form malignant tumors. The current therapy is limited by the highly ability of this disease to metastasize rapidly. Plumbagin is a naphthoquinone (5‐hydroxy‐2‐methyl‐1, 4‐naphthoquinone), isolated from the roots of medicinal plant Plumbago zeylanica, and it is widely present in Lawsonia inermis L . It has been shown that plumbagin has an anti‐proliferative and anti‐invasive activities in various cancer cell lines; however, the anti‐cancer and anti‐metastatic effects of plumbagin are largely unknown against melanoma cells. In this study, we evaluated the effect of plumbagin on B16F10 murine melanoma cells . Plumbagin decreased B16F10 cell viability as well as the cell migration, adhesion, and invasion. The molecular mechanism was studied, and plumbagin downregulated genes relevant in MAPK pathway, matrix metalloproteinases (MMP's), and cell adhesion. Furthermore, plumbagin elevated the expression of apoptosis and tumors suppressor genes, and genes significant in reactive oxygen species (ROS) response. Taken together, our findings suggest that plumbagin has an anti‐invasion and anti‐metastasis effect on melanoma cancer cells by acting on MAPK pathway and its related genes.
Melanoma is the most dangerous form of skin cancer with a very poor prognosis. Melanoma develops when unrepaired DNA damage causes to skin cells to multiply and form malignant tumors. The current therapy is limited by the highly ability of this disease to metastasize rapidly. Plumbagin is a naphthoquinone (5-hydroxy-2-methyl-1, 4-naphthoquinone), isolated from the roots of medicinal plant Plumbago zeylanica, and it is widely present in Lawsonia inermis L. It has been shown that plumbagin has an anti-proliferative and anti-invasive activities in various cancer cell lines; however, the anti-cancer and anti-metastatic effects of plumbagin are largely unknown against melanoma cells. In this study, we evaluated the effect of plumbagin on B16F10 murine melanoma cells . Plumbagin decreased B16F10 cell viability as well as the cell migration, adhesion, and invasion. The molecular mechanism was studied, and plumbagin downregulated genes relevant in MAPK pathway, matrix metalloproteinases (MMP's), and cell adhesion. Furthermore, plumbagin elevated the expression of apoptosis and tumors suppressor genes, and genes significant in reactive oxygen species (ROS) response. Taken together, our findings suggest that plumbagin has an anti-invasion and anti-metastasis effect on melanoma cancer cells by acting on MAPK pathway and its related genes.
Author Alem, Fatima‐Zahra
Rhourri‐Frih, Boutayna
Bejaoui, Meriem
Villareal, Myra O.
Isoda, Hiroko
Author_xml – sequence: 1
  givenname: Fatima‐Zahra
  surname: Alem
  fullname: Alem, Fatima‐Zahra
  organization: CNRS UMR 5248
– sequence: 2
  givenname: Meriem
  orcidid: 0000-0002-0607-6562
  surname: Bejaoui
  fullname: Bejaoui, Meriem
  organization: University of Tsukuba
– sequence: 3
  givenname: Myra O.
  orcidid: 0000-0003-4338-3323
  surname: Villareal
  fullname: Villareal, Myra O.
  organization: University of Tsukuba
– sequence: 4
  givenname: Boutayna
  surname: Rhourri‐Frih
  fullname: Rhourri‐Frih, Boutayna
  organization: CNRS UMR 5248
– sequence: 5
  givenname: Hiroko
  orcidid: 0000-0002-1399-9541
  surname: Isoda
  fullname: Isoda, Hiroko
  email: isoda.hiroko.ga@u.tsukuba.ac.jp
  organization: University of Tsukuba
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32012353$$D View this record in MEDLINE/PubMed
BookMark eNp10bFu1TAUBmALFdHbloEXQJZY6JD2OI6deCzlFlCLygASW-Q49q0rx05jh_YuPDtOb2GohBfLOp9-Hfk_QHs-eI3QGwInJJ9T_dCfkApq8QKtCAcogJdsD61AAC94DWwfHcR4C0BqWrNXaJ-WQErK6Ar9XrtZ2V4mGzwOBqcbjbUxWqXlNbp56OTG5pF_HA06yZiyVngMSftkpVvgB8IvCOBhnqxflJM-DBIr7VzEv6zEX8--XeJoN146Z_0GjzLd3MvtEXpppIv69dN9iH5crL-ffy6urj99OT-7KlTeUhSlUKLuqqYUknd9U8meSMM60VRMNZyXouuNrhg1DasZENmpHhSTPQVuKqVreoje73LHKdzNOqZ2sHHZTnod5tjmzwBBgFc803fP6G2Yp7z3ohrBgFEKWR3vlJpCjJM27TjZQU7blkC7lNLmUtrHUrJ9-5Q4d4Pu_8m_LWRwugP31unt_5Pa9c-Pu8g_UTyXXg
CitedBy_id crossref_primary_10_3390_pharmaceutics13050706
crossref_primary_10_2174_1389557520666201116144421
crossref_primary_10_1039_D3DT03806H
crossref_primary_10_2174_1568026623666230901124059
crossref_primary_10_1097_CMR_0000000000000873
Cites_doi 10.1016/j.jdermsci.2004.03.002
10.18632/oncotarget.5380
10.1039/C8RA05339A
10.1016/j.fct.2018.11.040
10.2147/CMAR.S6073
10.1016/j.fct.2019.01.018
10.1200/JCO.1999.17.7.2105
10.1016/j.devcel.2010.05.012
10.1002/jcb.22248
10.1038/sj.bjc.6603291
10.1056/NEJMoa1003466
10.1111/j.1742-4658.2012.08589.x
10.1371/journal.pone.0045023
10.1038/nrc1524
10.1021/acs.jnatprod.8b00964
10.1146/annurev-pathol-012513-104658
10.1038/nm1087
10.1158/1541-7786.MCR-08-0366
10.1016/j.intimp.2005.10.003
10.18632/oncotarget.4114
10.1186/s40360-016-0104-7
10.3389/fphar.2018.00856
10.1186/s12885-017-3892-2
10.1016/j.biopha.2018.02.052
10.1007/s00109-016-1452-x
10.1007/s10585-018-9893-y
10.1007/s00018-011-0878-0
10.1074/jbc.M112.421495
10.1101/gad.191999.112
10.1158/1541-7786.MCR-18-0327
10.1016/j.intimp.2009.03.022
10.2174/18715206113136660369
10.1242/jcs.092882
10.3109/09546634.2013.813897
10.1016/j.fitote.2004.03.009
10.3322/caac.21551
10.3390/ijms18020320
10.1038/nature12213
10.1046/j.1523-1747.2000.00068.x
10.1016/j.jep.2011.06.035
10.1111/bjd.15510
10.1177/1947601910373795
10.1093/nar/gkn923
ContentType Journal Article
Copyright 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Copyright_xml – notice: 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
– notice: 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
DBID NPM
AAYXX
CITATION
7T5
H94
7X8
DOI 10.1111/exd.14079
DatabaseName PubMed
CrossRef
Immunology Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
AIDS and Cancer Research Abstracts
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList AIDS and Cancer Research Abstracts
CrossRef
PubMed

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1600-0625
EndPage 435
ExternalDocumentID 10_1111_exd_14079
32012353
EXD14079
Genre article
Journal Article
GrantInformation_xml – fundername: Japan Student Services Organization (JASSO)
– fundername: University of Tsukuba
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
1OB
1OC
29G
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAKAS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AHEFC
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
CYRXZ
D-6
D-7
D-E
D-F
DC6
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
YFH
YUY
ZZTAW
~IA
~WT
NPM
AAYXX
CITATION
7T5
H94
7X8
ID FETCH-LOGICAL-c3539-29c97b4829a6bd84ad1af5b9845c86629bdfe453f857501abcd0c5ad306f4ce73
IEDL.DBID DR2
ISSN 0906-6705
IngestDate Fri Aug 16 02:08:52 EDT 2024
Thu Oct 10 16:20:38 EDT 2024
Fri Aug 23 00:33:22 EDT 2024
Sat Sep 28 08:28:37 EDT 2024
Sat Aug 24 01:07:16 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords MAPK pathway
migration
plumbagin
adhesion
invasion
metastasis
Language English
License 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3539-29c97b4829a6bd84ad1af5b9845c86629bdfe453f857501abcd0c5ad306f4ce73
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-4338-3323
0000-0002-1399-9541
0000-0002-0607-6562
PMID 32012353
PQID 2389505330
PQPubID 2045157
PageCount 9
ParticipantIDs proquest_miscellaneous_2350910646
proquest_journals_2389505330
crossref_primary_10_1111_exd_14079
pubmed_primary_32012353
wiley_primary_10_1111_exd_14079_EXD14079
PublicationCentury 2000
PublicationDate April 2020
2020-Apr
2020-04-00
20200401
PublicationDateYYYYMMDD 2020-04-01
PublicationDate_xml – month: 04
  year: 2020
  text: April 2020
PublicationDecade 2020
PublicationPlace Denmark
PublicationPlace_xml – name: Denmark
– name: Chichester
PublicationTitle Experimental dermatology
PublicationTitleAlternate Exp Dermatol
PublicationYear 2020
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2011; 137
2019; 2019
2015; 6
2006; 95
2000; 115
2010; 18
2018; 101
2010; 363
2019; 17
2013; 288
2014; 25
2006; 6
2019; 125
2017; 177
2012; 125
2016; 17
2019; 123
2004; 10
2017; 95
2018; 18
2018; 9
2004; 75
2018; 8
2019; 82
2010; 1
2002; 62
2004; 36
1999; 17
2017; 10
2005; 5
2013; 499
2009; 9
2014; 14
2009; 7
2017; 18
2012; 26
2012; 279
2012; 69
2009; 108
2010; 2
2012; 7
2016; 9
2009; 37
2018; 35
e_1_2_7_6_1
e_1_2_7_5_1
e_1_2_7_4_1
e_1_2_7_3_1
Bastian A. (e_1_2_7_37_1) 2017; 10
e_1_2_7_9_1
e_1_2_7_8_1
e_1_2_7_7_1
e_1_2_7_19_1
Brose M. S. (e_1_2_7_10_1) 2002; 62
e_1_2_7_18_1
e_1_2_7_17_1
e_1_2_7_16_1
e_1_2_7_40_1
e_1_2_7_2_1
e_1_2_7_15_1
e_1_2_7_41_1
e_1_2_7_14_1
e_1_2_7_42_1
e_1_2_7_13_1
e_1_2_7_43_1
e_1_2_7_12_1
e_1_2_7_44_1
e_1_2_7_11_1
e_1_2_7_45_1
e_1_2_7_46_1
e_1_2_7_26_1
e_1_2_7_27_1
e_1_2_7_28_1
e_1_2_7_29_1
e_1_2_7_30_1
e_1_2_7_25_1
e_1_2_7_31_1
e_1_2_7_24_1
e_1_2_7_32_1
e_1_2_7_23_1
e_1_2_7_33_1
e_1_2_7_22_1
e_1_2_7_34_1
e_1_2_7_21_1
e_1_2_7_35_1
e_1_2_7_20_1
e_1_2_7_36_1
e_1_2_7_38_1
e_1_2_7_39_1
References_xml – volume: 7
  start-page: 601
  year: 2009
  publication-title: Mol. Cancer Res.
– volume: 363
  start-page: 711
  year: 2010
  publication-title: N. Engl. J. Med.
– volume: 499
  start-page: 214
  year: 2013
  publication-title: Nature
– volume: 26
  start-page: 1131
  year: 2012
  publication-title: Genes Dev.
– volume: 177
  start-page: 134
  year: 2017
  publication-title: Br. J. Dermatol.
– volume: 10
  start-page: 5772
  year: 2017
  publication-title: Role Matrix Met Hum. Body Pathol.
– volume: 8
  start-page: 32022
  year: 2018
  publication-title: RSC Adv.
– volume: 9
  start-page: 949
  year: 2009
  publication-title: Int. Immunopharmacol.
– volume: 95
  start-page: 53
  year: 2017
  publication-title: J. Mol. Med.
– volume: 14
  start-page: 170
  year: 2014
  publication-title: Anticancer Agents Med. Chem.
– volume: 6
  start-page: 20636
  year: 2015
  publication-title: Oncotarget
– volume: 82
  start-page: 878
  year: 2019
  publication-title: J. Nat. Prod.
– volume: 137
  start-page: 752
  year: 2011
  publication-title: J. Ethnopharmacol.
– volume: 69
  start-page: 1475
  year: 2012
  publication-title: Cell Mol. Life Sci.
– volume: 17
  start-page: 199
  year: 2019
  publication-title: Mol. Cancer Res.
– volume: 2
  start-page: 197
  year: 2010
  publication-title: Cancer Manag. Res.
– volume: 123
  start-page: 492
  year: 2019
  publication-title: Food Chem. Toxicol.
– volume: 7
  year: 2012
  publication-title: PLoS ONE
– volume: 18
  start-page: 884
  year: 2010
  publication-title: Dev. Cell
– volume: 9
  start-page: 1
  year: 2018
  publication-title: Front. Pharmacol.
– volume: 25
  start-page: 401
  year: 2014
  publication-title: J. Dermatolog. Treat.
– volume: 5
  start-page: 51
  year: 2005
  publication-title: Nat. Rev. Cancer
– volume: 1
  start-page: 409
  year: 2010
  publication-title: Genes Cancer
– volume: 10
  start-page: 789
  year: 2004
  publication-title: Nat. Med.
– volume: 18
  start-page: 1
  year: 2018
  publication-title: BMC Cancer
– volume: 125
  start-page: 1693
  year: 2012
  publication-title: J. Cell Sci.
– volume: 75
  start-page: 500
  year: 2004
  publication-title: Fitoterapia
– volume: 115
  start-page: 337
  year: 2000
  publication-title: J. Invest. Dermatol.
– volume: 18
  start-page: 320
  year: 2017
  publication-title: Int. J. Mol. Sci.
– volume: 35
  start-page: 379
  year: 2018
  publication-title: Clin. Exp. Metastasis
– volume: 108
  start-page: 272
  year: 2009
  publication-title: J. Cell Biochem.
– volume: 279
  start-page: 2047
  year: 2012
  publication-title: FEBS J.
– volume: 17
  start-page: 1
  year: 2016
  publication-title: BMC Pharmacol. Toxicol.
– volume: 101
  start-page: 379
  year: 2018
  publication-title: Biomed Pharmacother.
– volume: 17
  start-page: 2105
  year: 1999
  publication-title: J. Clin. Oncol.
– volume: 125
  start-page: 566
  year: 2019
  publication-title: Food Chem. Toxicol.
– volume: 6
  start-page: 697
  year: 2006
  publication-title: Int. Immunopharmacol.
– volume: 6
  start-page: 38934
  year: 2015
  publication-title: Oncotarget
– volume: 9
  start-page: 239
  year: 2016
– volume: 288
  start-page: 6451
  year: 2013
  publication-title: J. Biol. Chem.
– volume: 2019
  start-page: 7
  year: 2019
  publication-title: CA Cancer J. Clin.
– volume: 36
  start-page: 71
  year: 2004
  publication-title: J. Dermatol. Sci.
– volume: 95
  start-page: 581
  year: 2006
  publication-title: Br. J. Cancer
– volume: 62
  start-page: 6997
  year: 2002
  publication-title: Cancer Res.
– volume: 37
  start-page: 1
  year: 2009
  publication-title: Nucleic Acids Res.
– ident: e_1_2_7_14_1
  doi: 10.1016/j.jdermsci.2004.03.002
– ident: e_1_2_7_35_1
  doi: 10.18632/oncotarget.5380
– ident: e_1_2_7_40_1
  doi: 10.1039/C8RA05339A
– ident: e_1_2_7_21_1
  doi: 10.1016/j.fct.2018.11.040
– volume: 62
  start-page: 6997
  year: 2002
  ident: e_1_2_7_10_1
  publication-title: Cancer Res.
  contributor:
    fullname: Brose M. S.
– ident: e_1_2_7_16_1
  doi: 10.2147/CMAR.S6073
– ident: e_1_2_7_46_1
  doi: 10.1016/j.fct.2019.01.018
– ident: e_1_2_7_15_1
  doi: 10.1200/JCO.1999.17.7.2105
– ident: e_1_2_7_28_1
  doi: 10.1016/j.devcel.2010.05.012
– ident: e_1_2_7_12_1
  doi: 10.1002/jcb.22248
– ident: e_1_2_7_34_1
  doi: 10.1038/sj.bjc.6603291
– ident: e_1_2_7_5_1
  doi: 10.1056/NEJMoa1003466
– ident: e_1_2_7_13_1
  doi: 10.1111/j.1742-4658.2012.08589.x
– ident: e_1_2_7_41_1
  doi: 10.1371/journal.pone.0045023
– ident: e_1_2_7_26_1
  doi: 10.1038/nrc1524
– ident: e_1_2_7_22_1
  doi: 10.1021/acs.jnatprod.8b00964
– ident: e_1_2_7_9_1
  doi: 10.1146/annurev-pathol-012513-104658
– ident: e_1_2_7_31_1
  doi: 10.1038/nm1087
– ident: e_1_2_7_32_1
  doi: 10.1158/1541-7786.MCR-08-0366
– ident: e_1_2_7_27_1
  doi: 10.1016/j.intimp.2005.10.003
– ident: e_1_2_7_44_1
  doi: 10.18632/oncotarget.4114
– ident: e_1_2_7_29_1
  doi: 10.1186/s40360-016-0104-7
– ident: e_1_2_7_39_1
  doi: 10.3389/fphar.2018.00856
– ident: e_1_2_7_3_1
  doi: 10.1186/s12885-017-3892-2
– ident: e_1_2_7_18_1
  doi: 10.1016/j.biopha.2018.02.052
– ident: e_1_2_7_36_1
  doi: 10.1007/s00109-016-1452-x
– ident: e_1_2_7_2_1
  doi: 10.1007/s10585-018-9893-y
– ident: e_1_2_7_45_1
  doi: 10.1007/s00018-011-0878-0
– ident: e_1_2_7_38_1
  doi: 10.1074/jbc.M112.421495
– ident: e_1_2_7_24_1
  doi: 10.1101/gad.191999.112
– ident: e_1_2_7_33_1
  doi: 10.1158/1541-7786.MCR-18-0327
– ident: e_1_2_7_19_1
  doi: 10.1016/j.intimp.2009.03.022
– volume: 10
  start-page: 5772
  year: 2017
  ident: e_1_2_7_37_1
  publication-title: Role Matrix Met Hum. Body Pathol.
  contributor:
    fullname: Bastian A.
– ident: e_1_2_7_42_1
  doi: 10.2174/18715206113136660369
– ident: e_1_2_7_43_1
  doi: 10.1242/jcs.092882
– ident: e_1_2_7_17_1
  doi: 10.3109/09546634.2013.813897
– ident: e_1_2_7_30_1
  doi: 10.1016/j.fitote.2004.03.009
– ident: e_1_2_7_6_1
  doi: 10.3322/caac.21551
– ident: e_1_2_7_20_1
  doi: 10.3390/ijms18020320
– ident: e_1_2_7_7_1
  doi: 10.1038/nature12213
– ident: e_1_2_7_11_1
  doi: 10.1046/j.1523-1747.2000.00068.x
– ident: e_1_2_7_25_1
  doi: 10.1016/j.jep.2011.06.035
– ident: e_1_2_7_4_1
  doi: 10.1111/bjd.15510
– ident: e_1_2_7_8_1
  doi: 10.1177/1947601910373795
– ident: e_1_2_7_23_1
  doi: 10.1093/nar/gkn923
SSID ssj0017375
Score 2.3535416
Snippet Melanoma is the most dangerous form of skin cancer with a very poor prognosis. Melanoma develops when unrepaired DNA damage causes to skin cells to multiply...
Abstract Melanoma is the most dangerous form of skin cancer with a very poor prognosis. Melanoma develops when unrepaired DNA damage causes to skin cells to...
SourceID proquest
crossref
pubmed
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 427
SubjectTerms adhesion
Apoptosis
Cell adhesion
Cell adhesion & migration
Cell migration
Cell viability
DNA damage
invasion
Invasiveness
MAP kinase
MAPK pathway
Matrix metalloproteinase
Medicinal plants
Melanoma
Metastases
Metastasis
migration
Plumbagin
Reactive oxygen species
Signal transduction
Skin cancer
Tumor cell lines
Tumors
Title Elucidation of the effect of plumbagin on the metastatic potential of B16F10 murine melanoma cells via MAPK signalling pathway
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fexd.14079
https://www.ncbi.nlm.nih.gov/pubmed/32012353
https://www.proquest.com/docview/2389505330
https://search.proquest.com/docview/2350910646
Volume 29
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VPVRcgJZXoCCDOHBJlcSxHYtToVtVoEUIUWkPSJGf0qrdZMVmeR347Xich1oQEuISJfLE77Fn7JlvAJ4jxJqXBUvLwlbh4YpU8dKk0ljppQ8KdIa-w_N3_Oy8fLNgix14OfrC9PgQ04EbckZcr5HBld5cYXL3zQY2zwQ67-VUoDnXyYcJOioXNILsZjJozFxkbEAVQiue6c_re9EfAuZ1eTVuOKe34NNY1d7O5OJo2-kj8-M3FMf_bMttuDkIouS4nzn7sOOaA9ibD1ftd-Dn7HJrln3EJdJ6EgRF0ht_4Nc6rGkaAxyRkIpJK9cpdE5aGrJuOzRBCpkHwlc5Dzo7WeGhPlJdqqZdKYL3BRvyZanI_Pj9W4JWJCqigxMMkfxVfb8L56ezj6_P0iFYQ2ooozItpJFCl1UhFde2KpXNlWdaViUzFeeF1Na7klGPIUGzXGljM8OUDSqLL40T9B7sNm3jHgCxhjmqjBey8iEfKhll2nkX1grBtRIJPBuHrV73mBz1qMuEnqxjTyZwOA5oPbDlpg7yiWTofZwl8HRKDgyFrVaNa7dIE2UoXvIE7vcTYSqFFtG3mCbwIg7n34uvZ4uT-PLw30kfwY0CtfloF3QIu93nrXscRJ5OP4lz-xd8J_wg
link.rule.ids 315,783,787,1378,27936,27937,46306,46730
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIkEvvEsDBQziwCVVNn4klrgUutVCuxVCrbQXFNmOLa3oJiuaBdpDf3s9zkMUhIS4RIk88XvsGXvmG4DXCLHmZMpjlpa5f9g0VoKZWJpSOum8Ap2g7_D0SExO2McZn63B294XpsWHGA7ckDPCeo0MjgfSv3C5_Vl6Pk8yeQNuenanGLhh7_MAHjXKaIDZTaTXmUWW8A5XCO14hl-v70Z_iJjXJdaw5ezfhS99ZVtLk687q0bvmIvfcBz_tzX34E4ni5LddvLchzVbPYBb0-62_SFcjk9XZt4GXSK1I15WJK39B34t_bKmMcYR8amYtLCNQv-kuSHLukErJJ-5J3w3El5tJws810eqU1XVC0XwyuCMfJ8rMt39dEDQkEQFgHCCUZJ_qPNHcLI_Pn4_ibt4DbGhnMo4lUZmmuWpVEKXOVPlSDmuZc64yYVIpS6dZZw6jAqajJQ2ZWK4Kr3W4pixGd2E9aqu7BaQ0nBLlXGZzJ3Ph0pOubbO-uUiE1plEbzqx61YtrAcRa_O-J4sQk9GsN2PaNFx5lnhRRTJ0QE5ieDlkOx5ClutKluvkCaIUYKJCB63M2EohabBvZhG8CaM59-LL8azvfDy5N9JX8DtyfH0sDj8cHTwFDZSVO6DmdA2rDffVvaZl4Aa_TxM9CstEwBH
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFH4qRaq4sC-BAgZx4JIqEy-JxanQGRXKVBWi0hyQIq_SiE4yohm2A78dP2cRBSEhLlEiv8Sxn5_9PfstAM8wxJqXOU9ZbstwcXmqBDOpNFZ66YMCnaHv8PxYHJ6yNwu-2IIXgy9MFx9i3HBDyYjzNQr42vpfhNx9tUHMs0JegstMBOSLiOjdGDtqUtAYZTeTQWUWRcb7sEJoxjO-enEx-gNhXgSsccWZXYMPw792hiYf9zat3jPffwvj-J-NuQ5XeyRK9ruhcwO2XH0Tdub9Wfst-DE925hll3KJNJ4EpEg66w98WodJTWOGIxJKsWjlWoXeSUtD1k2LNkjh44Hw5UQEpZ2scFcfqc5U3awUwQODc_J5qch8_-SIoBmJiuHBCeZI_qK-3YbT2fT9q8O0z9aQGsqpTHNpZKFZmUsltC2ZshPluZYl46YUIpfaesc49ZgTNJsobWxmuLKBc54ZV9A7sF03tbsHxBruqDK-kKUP36GSU66dd2GyKIRWRQJPB7ZV6y4oRzUoM6Enq9iTCewODK16uTyvAkCRHN2PswSejMVBorDVqnbNBmkiiBJMJHC3GwhjLTSPzsU0geeRnX-vvpouDuLN_X8nfQw7Jwez6u3r46MHcCVHzT7aCO3Cdvtp4x4G-NPqR3GY_wQxa_7n
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Elucidation+of+the+effect+of+plumbagin+on+the+metastatic+potential+of+B16F10+murine+melanoma+cells+via+MAPK+signalling+pathway&rft.jtitle=Experimental+dermatology&rft.au=Alem%2C+Fatima%E2%80%90Zahra&rft.au=Bejaoui%2C+Meriem&rft.au=Villareal%2C+Myra+O.&rft.au=Rhourri%E2%80%90Frih%2C+Boutayna&rft.date=2020-04-01&rft.issn=0906-6705&rft.eissn=1600-0625&rft.volume=29&rft.issue=4&rft.spage=427&rft.epage=435&rft_id=info:doi/10.1111%2Fexd.14079&rft.externalDBID=10.1111%252Fexd.14079&rft.externalDocID=EXD14079
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0906-6705&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0906-6705&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0906-6705&client=summon